NCT04747613: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 2 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04747613 |
|---|---|
| Title | An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 27, 2021 |
| Completion date | Oct. 19, 2027 |
| Required reporting date | Oct. 18, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 17, 2025 |
| Days late | None |